Borderlines between sarcopenia and mild late-onset muscle disease

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Palmio, Johanna ^a   Udd, Bjarne ^a,b,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE SEVERITY; GERIATRIC PATIENT; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DISEASE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIC DYSTROPHY; ONSET AGE; PATHOPHYSIOLOGY; SARCOPENIA;

EID: 84907181741     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00267     Document Type: Article

References (24)

1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F,et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing (2010) 39:412-23.
2. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med (2001) 137:231-43.
3. Correa-de-Araujo R, Hadley E. Skeletal muscle function deficit: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction. J Gerontol A Biol Sci Med Sci (2014) 69:591-4.
4. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging (2008) 12:433-50.
5. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci (2002) 57:M772-7.
6. Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int (2012) 12:388-96.
7. Patel HP, Syddall HE, Jameson K, Robinson S, Denison H, Roberts HC, et al. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing (2013) 42:378-84.
8. Doherty T. J. Physiology of aging. Invited review: aging and sarcopenia. J Appl Physiol (2003) 95:1717-27.
9. Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology (2008) 9:213-28.
10. Edstro¨m E, Altun M, Bergman E, Johnson H, Kullberg S, Rami´rez-Leo´n V, et al. Factors contributing to neuromuscular impairment and sarcopenia during aging. Physiol Behav (2007) 92:129-35.
11. Wattjes MP, Fischer D. "Normal aging muscle tissue." In: Wattjes MP, Fischer D, Editors. Neuromuscular imaging. New York, NY: Springer Science+Bisness Media (2013). p. 101-7.
12. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci (1988) 84:275-94.
13. Mu¨ller-Ho¨cker J. Mitochondria and ageing. Brain Pathol (1992) 2:149-58.
14. Nigro V, Savarese M. Invited review. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol (2014) 33:1-12.
15. Sarparanta J, Jonson PH, Golzio C, Sandell S, Luque H, Screen M, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limbgirdle muscular dystrophy. Nat Genet (2012) 44:450-5, S1-2.
16. Sandell S, Huovinen S, Sarparanta J, Luque H, Haapasalo H, Hackman P, et al. The enigma of 7q36 linked autosomal dominant limb girdle muscular dystrophy. J Neurol Neurosurg Psychiatry (2010) 81:834-9.
17. Penttila¨ S, Palmio J, Suominen T, Raheem O, Evila¨ A, Muelas Gomez N, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology (2012) 78:897-903.
18. Sandell S, Mahjneh I, Palmio J, Tasca G, Ricci E, Udd B. "Pathognomonic" muscle imaging findings in DNAJB6 mutated LGMD1D. Eur J Neurol (2013) 20:1553-9.
19. Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet (2011) 19:776-82.
20. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science (2001) 293:864-7.
21. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve (2005) 32:1-18.
22. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol (2012) 11:891-905.
23. Laguno M, Miro´ O, Perea M, Pico´n M, Urbano-Ma´rquez A, Grau JM. Muscle diseases in elders: a 10-year retrospective study. J Gerontol A Biol Sci Med Sci (2002) 57:M378-84.
24. Lacomis D, Chad DA, Smith TW. Myopathy in the elderly: evaluation of the histopathologic spectrum and the accuracy of clinical diagnosis. Neurology (1993) 43:825-8.